Compound Evidence File
#EC-2026-0768
Survodutide
Filed under Peptides. The bureau holds 125 laboratory returns for this compound from 34 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
34 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 10.0 | 10.0 | 23 May 2026 | 23 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 10.0 | 10.0 | 27 Mar 2026 | 4 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 9.9 | 10.0 | 13 Dec 2025 | 21 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 25 Apr 2026 | 19 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 10.0 | 9.9 | 10.0 | 3 Mar 2026 | 9 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 10.0 | 10.0 | 2 Feb 2026 | 13 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 25 Mar 2026 | 1 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 20 Jan 2026 | 11 Apr 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 9.9 | 10.0 | 6 May 2026 | 2 Aug 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 10.0 | 10.0 | 10.0 | 23 Feb 2026 | 24 May 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 10.0 | 10.0 | 10.0 | 3 Mar 2026 | 25 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 10.0 | 10.0 | 10.0 | 19 Jun 2026 | 24 Jun 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 9.9 | 9.9 | 10.0 | 5 Mar 2026 | 4 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 13 Dec 2025 | 5 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Apr 2026 | 5 Aug 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Jan 2026 | 5 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 7 Mar 2026 | 28 May 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 5 Apr 2026 | 8 Apr 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 9.9 | 14 May 2026 | 6 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 13 Jan 2026 | 10 Apr 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 9.9 | 2 Feb 2026 | 28 May 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 9.9 | 3 Jul 2026 | 1 Aug 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.9 | 7.7 | 9.8 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.6 | 7.1 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 5 | 8.6 | 8.1 | 9.3 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 8.5 | 8.1 | 9.2 | 25 May 2026 | 25 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.4 | 7.5 | 9.7 | 24 May 2026 | 24 May 2026 |
| Peptide-SCASE #VI-2026-0111 | A | 4 | 7.5 | 6.5 | 9.0 | 16 Jul 2025 | 25 Nov 2025 |
| Polaris PeptidesCASE #VI-2026-0839 | B | 5 | 7.3 | 5.9 | 8.8 | 25 Apr 2025 | 12 Aug 2025 |
| Qing Li PeptideCASE #VI-2026-0469 | A | 3 | 7.2 | 6.8 | 7.4 | 14 Jul 2025 | 3 Oct 2025 |
| Skye PeptidesCASE #VI-2026-0451 | B | 4 | 6.8 | 6.1 | 7.3 | 6 May 2025 | 21 May 2025 |
| UtherCASE #VI-2026-0902 | D | 3 | 6.5 | 3.7 | 8.6 | 9 Oct 2025 | 23 Oct 2025 |
| Paramount PeptidesCASE #VI-2026-0550 | C | 3 | 5.2 | 4.6 | 6.0 | 25 Apr 2025 | 6 May 2025 |
Open any subject to view the batch-level evidence for Survodutide alone.